Evidence map›Paper›PMID 41444829›Full record

ArticleNature nanotechnology2026

Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature.

Dana Goerzen, Mijin Kim, Chanel Schroff, Margaret Ngoc Hoang, Jaina Sarris Wollowitz, August Kolb, Jordain P Walshon, Kathleen McCortney, Craig Horbinski, Kristyn Galbraith and 4 more

Abstract read
In one paragraph

Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dana GoerzenMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9645-3503
Mijin Kim *Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7781-9466
Chanel Schroff *Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0009-0005-2844-2075
Margaret Ngoc HoangMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jaina Sarris WollowitzMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5938-4382
August KolbDepartment of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0009-0002-1173-6147
Jordain P WalshonDepartment of Neurosurgery, Northwestern University, Chicago, IL, USA.
Kathleen McCortneyDepartment of Neurosurgery, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-7085-830X
Craig HorbinskiDepartment of Neurosurgery, Northwestern University, Chicago, IL, USA.
Kristyn GalbraithDepartment of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, USA.
Sana RaoofMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Matija SnuderlDepartment of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, USA.
Alban OrdureauMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4924-8520
Daniel A HellerMemorial Sloan Kettering Cancer Center, New York, NY, USA. hellerd@mskcc.org.ORCID http://orcid.org/0000-0002-6866-0000

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hui Zhang · 2018 to 2026
$21.4M
Inducing Neural Maturation in Medulloblastoma by Targeting EZH2R01NS122987 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAJU, PRAVEEN B., SNUDERL, MATIJA · 2022 to 2025
$2.8M
Nanosensor Array Platform to Capture Whole Disease FingerprintsR01EB033651 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2023 to 2026
$2.6M
Tri-Institutional PhD Program in Chemical BiologyT32GM136640 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEREK S TAN · 2020 to 2026
$2.4M
Decoding the Ubiquitin and Autophagy Signaling NetworksR35GM156454 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI Alban Ordureau · 2025 to 2026
$880k
Machine Perception Nanosensor Array Platform to Capture Whole Disease Fingerprints of Early Stage Pancreatic CancerR00EB033580 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI Mijin Kim · 2024 to 2026
$692k
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221747NIBIB NIH HHS R00 EB033580NIBIB NIH HHS R01 EB033651NIGMS NIH HHS R35 GM156454NIGMS NIH HHS T32 GM136640NINDS NIH HHS R01 NS122987
6 · The paper itself

Abstract

The detection and identification of intracranial tumours is limited by the lack of accurate biomarkers and requires invasive biopsy procedures. We investigated a machine perception liquid biopsy approach to detect and identify intracranial tumours from peripheral blood and to discover biomarkers responsible for the predictions. Quantum well defect-modified single-walled carbon nanotubes stabilized with single-stranded DNA, interrogating 739 plasma samples from brain tumour patients, were used to train and validate machine-learning models to detect intracranial tumours with 98% accuracy and identify tumour type. The protein corona of the top model-contributing nanosensor was interrogated using quantitative proteomics, resulting in the identification of tumour ecosystem-secreted factors, both previously reported and newly discovered, originating from intracranial tumour cells, the tumour microenvironment and the innate immune system of patients with glioblastoma and meningioma. Newly discovered factors elicited linear nanosensor responses and were elevated in one or both tumour types, matching the original protein corona enrichment. This investigation reveals that a perception-based detection of disease in blood can identify biomarkers responsible for the signal and also amplify cancer detection signals by detecting factors beyond tumour cells, thereby recruiting the entire tumour ecosystem for cancer diagnosis.

Indexed as

Biomarkers, TumorBrain NeoplasmsGlioblastomaMachine LearningMeningiomaTumor MicroenvironmentFemaleHumansLiquid BiopsyMaleMiddle AgedNanotubes, CarbonProtein CoronaProteomicsBiomarkers, TumorNanotubes, CarbonProtein Corona

Identifiers

PMID41444829
PMCPMC12916486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.